Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance

Resistant CMV infections are challenging complications after SOT and HSCT. Prompt recognition of ARMs is imperative for appropriate therapy. 108 plasma samples from 96 CMV + transplant recipients with suspected resistance were analysed in CNM in a retrospective nationwide study from January 2018 to...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Virology journal Ročník 20; číslo 1; s. 153
Hlavní autori: Recio, Vanessa, González, Irene, Tarragó, David
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 18.07.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Analysis
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Biomedical and Life Sciences
Biomedicine
Care and treatment
Cloning
Cytomegalovirus
Cytomegalovirus - genetics
Cytomegalovirus infections
Cytomegalovirus Infections - drug therapy
Diagnosis
Disease prevention
Drug resistance
Drug Resistance, Viral - genetics
E coli
FDA approval
Ganciclovir - therapeutic use
Gene mutations
Genes
Genetic aspects
Genotyping
Humans
Kidney transplants
Lung transplants
Mutation
Nucleoside analogs
nucleosides
Patient outcomes
Patients
Phosphotransferases (Alcohol Group Acceptor) - genetics
Phosphotransferases (Alcohol Group Acceptor) - therapeutic use
Plasmids
Resistance mutations to antivirals
Retrospective Studies
Risk factors
Software
Statistical analysis
Stem cell transplantation
therapeutics
Transplant patients
Transplant Recipients
UL54 gene
UL56 gene
UL97 gene
Virology
Spain
United States > US
Transplant patients
Cytomegalovirus
Letermovir
Ganciclovir
Foscarnet
Resistance mutations to antivirals
Hematopoietic stem cells transplant
Solid organ transplant
UL97 gene
UL54 gene
UL56 gene
ISSN:1743-422X, 1743-422X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Resistant CMV infections are challenging complications after SOT and HSCT. Prompt recognition of ARMs is imperative for appropriate therapy. 108 plasma samples from 96 CMV + transplant recipients with suspected resistance were analysed in CNM in a retrospective nationwide study from January 2018 to July 2022 for resistance genotyping. ARMs in UL97 and UL54 were found in 26.87% (18/67) and 10.60% (7/66) of patients, respectively. Patients’ ARM distribution in UL97 was as follows: L595S n = 3; L595S/M460I n = 1; L595S/N510S n = 1; L595W n = 1; C603W n = 4; A594V n = 3; A594E n = 1; C607Y n = 1; L397R/T409M/H411L/M460I n = 1; L397I n = 1; H520Q n = 1; four patients showed ARMs in UL54 as well (F412C n = 1; T503I n = 2; P522S n = 1), whereas three patients exhibited ARMs in UL54 only (L501I/T503I/L516R/A834P n = 1; A987G n = 2). L516R in UL54 and L397R/I and H411L in UL97 have been found for the first time in a clinical sample. L595S/W was the most prevalent ARM found to lend resistance to GCV. In UL54 all ARMs lent resistance to GCV and CDV. In addition, A834P, found in one patient, also lent resistance to FOS. CMV load did not differ significantly in patients with or without ARMs, and no differences were found either between patients with ARMs in UL97 or in UL97 and UL54. Despite extensive use of classical antivirals for the treatment of CMV infection after HSCT and SOT, ARMs occurred mainly in viral UL97 kinase, which suggests that CDV and mostly FOS continue to be useful alternatives to nucleoside analogues after genotypic detection of ARMs.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1743-422X
1743-422X
DOI:10.1186/s12985-023-02127-7